Utilization of genomic sequence information to develop malaria vaccines

Journal of Experimental Biology

Volumn 206, Issue 21, 2003, Pages 3789-3802

  Doolan, D L ^a,b   Aguiar, J C ^a,c   Weiss, W R ^a   Sette, A ^e   Felgner, P L ^f   Regis, D P ^a   Quinones Casas, P ^a,d   Yates III, J R ^g   Blair, P L ^a   Richie, T L ^a   Hoffman, S L ^a,h   Carucci, D J ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c PAN AMERICAN HEALTH ORGANIZATION   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

^h SANARIA INC   (United States)

Author keywords

Genomics; Molecular immunology, immune screening, multi epitope; P. falciparum; Plasmodium; Proteomics; Vaccine

Indexed keywords

ANIMALS; ANTIGENS, PROTOZOAN; EPITOPES; GENE EXPRESSION; GENOME, PROTOZOAN; MALARIA VACCINES; MODELS, IMMUNOLOGICAL; OPEN READING FRAMES; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PROTEIN ARRAY ANALYSIS; VACCINES, SYNTHETIC;

PLASMODIUM FALCIPARUM;

EID: 10744220951     PISSN: 00220949     EISSN: None     Source Type: Journal    
DOI: 10.1242/jeb.00615     Document Type: Review

References (89)

1. Bahl, A., Brunk, B., Crabtree, J., Fraunholz, M. J., Gajria, B., Grant, G. R., Ginsburg, H., Gupta, D., Kissinger, J. C., Labo, P. et al. (2003). PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data. Nucleic Acids Res. 31, 212-215.
2. Baird, J. (1995). Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. Parasitol. Today 11, 105-111.
3. Baird, J. K. (1998). Age-dependent characteristics of protection versus susceptibility to Plasmodium falciparum. Ann. Trop. Med. Parasitol. 92, 367-390.
4. Berzins, K. and Perlmann, P. (1996). Malaria vaccines: attacking infected erythrocytes. In Malaria Vaccine Development: A Multi-Immune Response Approach (ed. S. L Hoffman), pp. 105-144. Washington, DC: ASM Press.
5. Bouharoun-Tayoun, H., Oeuvray, C., Lunel, F. and Druilhe, P. (1995). Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 182, 409-418.
6. Breman, J. G. (2001). Ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 64, 1-11.
7. Brizuela, L., Braun, P. and Labaer, J. (2001). FLEXGene repository: from sequenced genomes to gene repositories for high-throughput functional biology and proteomics. Mol. Biochem. Parasit. 118, 155-165.
8. Brown, G. and Rogerson, S. J. (1996). Preventing cytoadherence of infected erythrocytes to endothelial cells and noninfected erythrocytes. In Malaria Vaccine Development: A Multi-Immune Response Approach (ed. S. L Hoffman), pp. 145-166. Washington, DC: ASM Press.
9. Carlton, J. M., Angiuoli, S. V., Suh, B. B., Kooij, T. W., Pertea, M., Silva, J. C., Ermolaeva, M. D., Allen, J. E., Selengut, J. D., Koo, H. L. et al. (2002). Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. Nature 419, 512-519.
10. Clark, I. A. and Schofield, L. (2000). Pathogenesis of malaria. Parasitol. Today 16, 451-454.
11. Clyde, D. F., McCarthy, V. C., Miller, R. M. and Hornick, R. B. (1973), Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 266, 398-401.
12. Clyde, D. F., Most, H., McCarthy, V. C. and Vanderberg, J. P. (1973). Immunization of man against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 266, 169-177.
13. Cohen, S., McGregor, I. A. and Carrington, S. (1961). Gamma-globulin and acquired immunity to human malaria. Nature 192, 733-737.
14. Collins, W. E. (2002). Nonhuman primate models. I. Nonhuman primate host-parasite combinations. Methods Mol. Med. 72, 77-84.
15. Collins, W. E. and Jeffery, G. M. (1999a). A retrospective examination of sporozoite-and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity during primary infection. Am. J. Trop. Med. Hyg. 61, 4-19.
16. Collins, W. E. and Jeffery, G. M. (1999b). A retrospective examination of secondary sporozoite-and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Am. J. Trop. Med. Hyg. 61, 20-35.
17. Doolan, D. L. and Hoffman, S. L. (1997). Multi-gene vaccination against malaria: a multi-stage, multi-immune response approach. Parasitol. Today 13, 171-178.
18. + T cells. J. Immunol. 163, 884-892.
19. Doolan, D. L. and Hoffman, S. L. (2000). The complexity of protective immunity against liver-stage malaria. J. Immunol. 165, 1453-1462.
20. Doolan, D. L. and Hoffman, S. L. (2001). DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. Int. J. Parasitol. 31, 753-762.
21. Doolan, D. L., Hoffman, S. L., Southwood, S., Wentworth, P. A., Sidney, J., Chesnut, R. W., Keogh, E., Appella, E., Nutman, T. B., Lal, A. A. et al. (1997). Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 7, 97-112.
22. + T cell, interferon-γ, nitric oxide dependent immunity. J. Exp. Med. 183, 1739-1746.
23. Doolan, D. L., Southwood, S., Chesnut, R., Appella, E., Gomez, E., Richards, A., Higashimoto, Y. I., Maewal, A., Sidney, J., Gramzinski, R. A. et al. (2000). HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J. Immunol. 165, 1123-1137.
24. Doolan, D. L., Southwood, S., Freilich, D. A., Sidney, J., Graber, N. L., Shatney, L., Bebris, L., Florens, L., Dobano, C., Witney, A. A. et al. (2003). Identification of new P. falciparum antigens by antigenic analysis of genomic and proteomic data. Proc. Natl. Acad. Sci. USA 100, 9952-9957.
25. Duffy, P. E., Craig, A. G. and Baruch, D. I. (2001). Variant proteins on the surface of malaria-infected erythrocytes - developing vaccines. Trends Parasitol. 17, 354-356.
26. Dunachie, S. J. and Hill, A. V. S. (2003). Prime-boost strategies for malaria vaccine development. J. Exp. Biol. 206, 3771-3779.
27. Florens, L., Washburn, M. P., Raine, J. D., Anthony, R. M., Grainger, M., Haynes, J. D., Moch, J. K., Muster, N., Sacci, J. B., Tabb, D. L. et al. (2002). A proteomic view of the Plasmodium falciparum life cycle. Nature 419, 520-526.
28. Gallup, J. L. and Sachs, J. D. (2001). The economic burden of malaria. Am. J. Trop. Med. Hyg. 64, 85-96.
29. Gardner, M. J., Shallom, S. J., Carlton, J. M., Salzberg, S. L., Nene, V., Shoaibi, A., Ciecko, A., Lynn, J., Rizzo, M., Weaver, B. et al. (2002). Sequence of Plasmodium falciparum chromosomes 2, 10, 11 and 14. Nature 419, 531-534.
30. Good, M. F. and Doolan, D. L. (1999). Immune effector mechanisms in malaria. Curr. Opin. Immunol. 11, 412-419.
31. Gygi, S. P., Rochon, Y., Franza, B. R. and Aebersold, R. (1999). Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19, 1720-1730.
32. Hayward, R. E., Derisi, J. L., Alfadhli, S., Kaslow, D. C., Brown, P. O. and Rathod, P. K. (2000). Shotgun DNA microarrays and stage-specific gene expression in Plasmodium falciparum malaria. Mol. Microbiol. 35, 6-14.
33. Hoffman, S. L., Rogers, W. O., Carucci, D. J. and Venter, J. C. (1998). From genomics to vaccines: malaria as a model system. Nat. Med. 4, 1351-1353.
34. Hoffman, S. L., Goh, L. M., Luke, T. C., Schneider, I., Le, T. P., Doolan, D. L., Sacci, J., de la Vega, P., Dowler, M., Paul, C. et al. (2002a). Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155-1164.
35. Hoffman, S. L., Subramanian, G. M., Collins, F. H. and Venter, J. C. (2002b). Plasmodium, human and Anopheles genomics and malaria. Nature 415, 702-709.
36. Hoffman, S. L., Doolan, D. L. and Richie, T. L. (in press). Malaria: a complex disease that may require a complex vaccine. In New Generation Vaccines (ed. M. M. Levine, J. B. Kaper, R. Rappuoli, M. Liu and M. F. Good). New York, NY: Marcel Dekker, Inc.
37. Holder, A. A. (1996). Preventing merozoite invasion of erythrocytes. In Malaria Vacćine Development (ed. S. L. Hoffman), pp. 77-104. Washington, DC: ASM Press.
38. Holt, R. A., Subramanian, G. M., Halpern, A., Sutton, G. G., Charlab, R., Nusskern, D. R., Wincker, P., Clark, A. G., Ribeiro, J. M., Wides, R. et al. (2002). The genome sequence of the malaria mosquito Anopheles gambiae. Science 298, 129-149.
39. Jeffery, G. M. (1966). Epidemiological significance of repeated infections with homologous and heterologous strains and species of Plasmodium. Bull. World Health Org. 35, 873-882.
40. Kappe, S. H., Gardner, M. J., Brown, S. M., Ross, J., Matuschewski, K., Ribeiro, J. M., Adams, J. H., Quackenbush, J., Cho, J., Carucci, D. J. et al. (2001). Exploring the transcriptome of the malaria sporozoite stage. Proc. Natl. Acad. Sci. USA 98, 9895-9900.
41. Lalvani, A., Moris, P., Voss, G., Pathan, A. A., Kester, K. E., Brookes, R., Lee, E., Koutsoukos, M., Plebanski, M., Delchambre, M. et al., (1999). Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J. Infect. Dis. 180, 1656-1664.
42. Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W. et al. (2001). Initial sequencing and analysis of the human genome. Nature 409, 860-921.
43. Lasonder, E., Ishihama, Y., Andersen, J. S., Vermunt, A. M., Pain, A., Sauerwein, R. W., Eling, W. M., Hall, N., Waters, A. P., Stunnenberg, H. G. et al., (2002). Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature 419, 537-542.
44. Le Roch, K. G., Zhou, Y., Blair, P. L., Grainger, M., Moch, J. K., Haynes, J. D., De La Vega, P., Holder, A. A., Batalov, S., Carucci, D. J. et al. (2003). Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 31 July (Epub ahead of print).
45. Liang, X., Teng, A., Braun, D. M., Felgner, J., Wang, Y., Baker, S. I., Chen, S., Zelphati, O. and Feigner, P. L. (2002). Transcriptionally active polymerase chain reaction (TAP): high throughput gene expression using genome sequence data. J. Biol. Chem. 211, 3593-3598.
46. Mahanty, S., Saul, A. and Miller, L. H. (2003). Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J. Exp. Biol. 206, 3781-3788.
47. Marsh, K., English, M., Crawley, J. and Peshu, N. (1996). The pathogenesis of severe malaria in African children. Ann. Trop. Med. Parasitol. 90, 395-402.
48. Mbogo, C. N., Snow, R. W., Khamala, C. P., Kabiru, E. W., Ouma, J. H., Githure, J. I., Marsh, K. and Beier, J. C. (1995). Relationships between Plasmodium falciparum transmission by vector populations and the incidence of severe disease at nine sites on the Kenyan coast. Am. J. Trop. Med. Hyg. 52, 201-206.
49. McConkey, S. J., Reece, W. H., Moorthy, V. S., Webster, D., Dunachie, S., Butcher, G., Vuola, J. M., Blanchard, T. J., Gotnard, P., Watkins, K. et al. (2003). Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9, 729-735.
50. McElroy, P. D., Beier, J. C., Oster, C. N., Beadle, C., Sherwood, J. A., Oloo, A. J. and Hoffman, S. L. (1994). Predicting outcome in malaria: correlation between rate of exposure to infected mosquitoes and level of Plasmodium falciparum parasitemia. Am. J. Trop. Med. Hyg. 51, 523-532.
51. McElroy, P. D., Beier, J. C., Oster, C. N., Onyango, F. K., Oloo, A. J., Lin, X., Beadle, C. and Hoffman, S. L. (1997). Dose-and time-dependent relations between infective Anopheles inoculation and outcomes of Plasmodium falciparum parasitemia among children in western Kenya. Am. J. Epidemiol. 145, 945-956.
52. McGregor, I. A. and Carrington, S. P. (1963). Treatment of East African P. falciparum malaria with West African human gamma-globulin. Trans. R. Soc. Trop. Med. Hyg. 57, 170-175.
53. Miller, L. H., Good, M. F. and Milon, G. (1994). Malaria pathogenesis. Science 264, 1878-1883.
54. Moorthy, V. and Hill, A. V. (2002). Malaria vaccines. Br. Med. Bull. 62, 59-72.
55. Nussenzweig, V. and Nussenzweig, R. S. (1989). Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 45, 283-334.
56. Nussenzweig, R. S., Vanderberg, J., Most, H. and Orton, C. (1967). Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 216, 160-162.
57. Playfair, J. H. L. (1996). An antitoxic vaccine for malaria? In Malaria Vaccine Development: A Multi-Immune Response Approach (ed. S. L Hoffman), pp. 167-180. Washington, DC: ASM Press.
58. Plebanski, M. and Hill, A. V. (2000). The immunology of malaria infection. Curr. Opin. Immunol. 12, 437-441.
59. Rathod, P. K., Ganesan, K., Hayward, R. E., Bozdech, Z. and DeRisi, J. L. (2002). DNA microarrays for malaria. Trends Parasitol. 18, 39-45.
60. Renia, L., Belnoue, E. and Landau, I. (2002). Mouse models for preerythrocytic-stage malaria. Methods Mol. Med 72, 41-55.
61. Richie, T. L. and Saul, A. (2002). Progress and challenges for malaria vaccines. Nature 415, 694-701.
62. Rogers, W. O., Baird, J. K., Kumar, A., Tine, J. A., Weiss, W., Aguiar, J. C., Gowda, K., Gwadz, R., Kumar, S., Gold, M. et al. (2001). Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect. Immun. 69, 5565-5572.
63. Sabchareon, A., Burnouf, T., Ouattara, D., Attanath, P., Bouharoun-Tayoun, H., Chantavanich, P., Foucault, C., Chongsuphajaisiddhi, T. and Druilhe, P. (1991). Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am. J. Trop. Med. Hyg. 45, 297-308.
64. Sacci, J. B., Jr, Aguiar, J. C., Lau, A. O. and Hoffman, S. L. (2002). Laser capture microdissection and molecular analysis of Plasmodium yoelii liver-stage parasites. Mol. Biochem. Parasitol. 119, 285-289.
65. Sanni, L. A., Fonseca, L. F. and Langhorne, J. (2002). Mouse models for erythrocytic-stage malaria. Methods Mol. Med. 72, 57-76.
66. + T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 170, 29-38.
67. Schofield, L., Hewitt, M. C., Evans, K., Siomos, M. A. and Seeberger, P. H. (2002). Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 418, 785-789.
68. Sedegah, M., Hedstrom, R. C., Hobart, P. and Hoffman, S. L. (1994). Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl. Acad. Sci. USA 91, 9866-9870.
69. Sedegah, M., Charoenvit, Y., Minh, L., Belmonte, M., Fallarme, V., Abbot, S., Ganeshan, H., Sacci, J., Kumar, S., Meek, J. et al. (in press). Reduced immunogenicity of P. falciparum DNA vaccine plasmids in a nine-plasmid mixture. J. Immunol.
70. Sedegah, M., Tosta, C. E., Henderson, D. C. and Wedderburn, N. (1982). Cross-reactivity and cross-protection in murine malaria. Ann. Trop. Med. Parasitol. 76, 219-221.
71. Sette, A. and Sidney, J. (1998). HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr. Opin. Immunol. 10, 478-482.
72. Sette, A. and Sidney, J. (1999). Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50, 201-212.
73. Sette, A., Livingston, B., McKinney, D., Appella, E., Fikes, J., Sidney, J., Newman, M. and Chesnut, R. (2001). The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 29, 271-276.
74. Sette, A., Keogh, E., Ishioka, G., Sidney, J., Tangri, S., Livingston, B., McKinney, D., Newman, M., Chesnut, R. and Fikes, J. (2002). Epitope identification and vaccine design for cancer immunotherapy. Curr. Opin. Investig. Drugs 3, 132-139.
75. Sim, B. K., Narum, D. L., Liang, H., Fuhrmann, S. R., Obaldia, N., 3rd, Gramzinski, R., Aguiar, J., Haynes, J. D., Moch, J. K. and Hoffman, S. L. (2001). Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Mol. Med. 7, 247-254.
76. Sinnis, P. and Nussenzweig, V. (1996). Preventing sporozoite invasion of hepatocytes. In Malaria Vaccine Development: A Multi-Immune Response Approach (ed. S. L Hoffman), pp. 15-34. Washington, DC: ASM Press.
77. Snow, R. W., Nahlen, B., Palmer, A., Donnelly, C. A., Gupta, S. and Marsh, K. (1998). Risk of severe malaria among African infants: direct evidence of clinical protection during early infancy. J. Infect. Dis. 177, 819-822.
78. Southwood, S., Sidney, J., Kondo, A., del Guercio, M. F., Appella, E., Hoffman, S., Kubo, R. T., Chesnut, R. W., Grey, H. M. and Sette, A. (1998). Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160, 3363-3373.
79. Sykes, K. F. and Johnston, S. A. (1999). Linear expression elements: a rapid, in vivo, method to screen for gene functions. Nat. Biotech. 17, 355-359.
80. Thompson, J., Janse, C. J. and Waters, A. P. (2001). Comparative genomics in Plasmodium: a tool for the identification of genes and functional analysis. Mol. Biochem. Parasitol. 118, 147-154.
81. Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A. et al. (2001). The sequence of the human genome. Science 291, 1304-1351.
82. Vounatsou, P., Smith, T., Kitua, A. Y., Alonso, P. L. and Tanner, M. (2000). Apparent tolerance of Plasmodium falciparum in infants in a highly endemic area. Parasitology 120, 1-9.
83. Washburn, M. P., Ulaszek, R., Deciu, C., Schieltz, D. M. and Yates, J. R., III (2002). Analysis of quantitative proteomic data generated via multidimensional protein identification technology. Anal. Chem. 74, 1650-1657.
84. Waters, A. P. (2002). Orthology between the genomes of Plasmodium falciparum and rodent malaria parasites: possible practical applications. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 357, 55-63.
85. Wickham, M. E., Thompson, J. K. and Cowman, A. F. (2003). Characterisation of the merozoite surface protein-2 promoter using stable and transient transfection in Plasmodium falciparum. Mol. Biochem. Parasitol. 129, 147-156.
86. Wirth, D. F. (2002). Biological revelations. Nature 419, 495-496.
87. Witney, A. A., Doolan, D. L., Anthony, R. M., Weiss, W. R., Hoffman, S. L. and Carucci, D. J. (2001). Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy. Mol. Biochem. Parasitol. 118, 233-245.
88. World Health Organization (2002). WHO Report, http://www.who.int/ infections-disease-report/2002/index. html.
89. Zapata, J. C., Perlaza, B. L., Hurtado, S., Quintero, G. E., Jurado, D., Gonzalez, I., Druilhe, P., Arevalo-Herrera, M. and Herrera, S. (2002). Reproducible infection of intact Aotus lemurinus griseimembra monkeys by Plasmodium falciparum sporozoite inoculation. J. Parasitol. 88, 723-729.